Lilly will acquire our mutant-selective PI3Kα inhibitor program, led by STX-478, a promising, next-generation treatment currently in Phase 1/2 trials for breast cancer and other advanced solid ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...

To further bolster its pursuit of becoming a leading player in the oncology market, Lilly also recently announced that it is acquiring a clinical stage drug known as STX-478 from Scorpion ...

Meanwhile, Eli Lilly announced plans to acquire Scorpion Therapeutics’ STX-478, a P13K inhibitor which is in phase I trials for breast cancer and other advanced solid tumours. GSK flagged the US ...